Quris Earns Frost & Sullivan 2022 Europe Know-how Innovation Management Award for AI-Powered Drug Security Prediction

Analysts discovered that the Quris Bio-AI Medical Prediction Platform enhances drug improvement course of agility, shortens discovery timelines, will increase drug security, and improves drug pipeline diversification alternatives

SAN ANTONIO, Aug. 31, 2022 /CNW/ — Frost & Sullivan just lately researched the synthetic intelligence (AI)-enabled drug security prediction know-how trade and, based mostly on its findings, acknowledges Quris with the 2022 Europe Know-how Innovation Management Award. The modern Quris Bio-AI Medical Prediction Platform is the primary AI breakthrough to shut the scientific prediction hole by successfully predicting which drug candidates will work safely in people.

Get entry to extra particulars on the award multi-media web page – https://best-practices.frost.com/quris-technologies/

“Quris AI Chip-on-Chip platform, in contrast to different AI-pharma options specializing in drug discovery, higher signifies which drug candidates will safely work in people. It makes use of AI to foretell a drug’s security, and therefore its capacity to succeed, significantly in Part 1 trials, thus avoiding the excessive prices of failed scientific trials for pharmaceutical corporations,” mentioned Supriya Lala Kundu, a Greatest Practices Analysis analyst at Frost & Sullivan.

The corporate’s platform scales to suit the intricacies of scientific prediction, requiring machine studying (ML)  fashions to routinely run an unlimited variety of organic Sufferers-on-a-Chip experiments for AI coaching. Quris’s AI Chip-on-Chip know-how leverages a patented course of to check hundreds of recognized protected and unsafe medicine on hundreds of miniaturized Sufferers-on-a-Chip making use of an automatic, high-throughput system. Equally, next-generation nano-sensors allow steady response monitoring from every miniaturized organ to those medicine. Furthermore, steady knowledge era additional trains the ML classification algorithm, making it extremely predictive of scientific security and enabling it to higher discern the toxicity stage of latest drug candidates throughout testing. The modern and ground-breaking platform simulates a pure human physique’s response to novel molecules with out counting on inaccurate animal testing – decreasing animal cruelty throughout pre-clinical experimentation because of its potential to restrict dependence on animal testing.

Ashish Kaul, an trade analyst for Frost & Sullivan, mentioned, “In contrast to different organ-chip units with restricted capacity to run thousands and thousands of experiments, the Quris platform is extremely scalable, enabling large experiments to run cost-effectively and practice the AI, thereby revolutionizing the pharmaceutical trade. Moreover, the platform can scale as much as 1,000 medicine throughout all therapeutics, notably oncology, uncommon illness, and the blood-brain barrier.”

Quris stands out from opponents based mostly on its dedication to innovation and creativity whereas attaining business success. Along with its drug security prediction pharma companies, Quris additionally has a drug pipeline and offers personalised drugs companies. The corporate has a workforce of scientists, know-how specialists, medical pioneers, and seasoned administration professionals with a observe report of seamless execution. Its sturdy mental property portfolio protects its pioneering know-how, including worth relative to its progress potential, thus securing a aggressive benefit. Its first AI-based Fragile-X drug is making ready for scientific testing later in 2022. Moreover, the corporate has established stem cell facilities worldwide to supply personalised drugs companies, additional validating its platform and enabling it to develop by strategic partnerships with trade and analysis institutes.

“Recognition by the Frost & Sullivan workforce additional validates our mission to utterly rethink drug improvement and resolve the most important drug discovery problem of our period – utilizing AI scientific prediction to take away longstanding obstacles for the whole pharma trade. Permitting the environment friendly discovery of latest medicine and the repurposing/personalization of current medicine, Quris will assist pharma corporations keep away from the large dangers and prices of failed scientific trials and finish the reliance on ineffective animal testing,” added Quris Founder and CEO Isaac Bentwich.

Annually, Frost & Sullivan presents this award to the corporate that develops a product with modern options and performance that’s gaining fast acceptance available in the market. The award acknowledges the standard of the answer and the shopper worth enhancements it allows.

Frost & Sullivan Greatest Practices awards acknowledge corporations in varied regional and world markets for demonstrating excellent achievement and superior efficiency in management, technological innovation, customer support, and strategic product improvement. Trade analysts evaluate market members and measure efficiency by in-depth interviews, analyses, and in depth secondary analysis to establish greatest practices within the trade.

About Frost & Sullivan

For six a long time, Frost & Sullivan has been world-renowned in serving to traders, company leaders, and governments navigate financial adjustments and establish disruptive applied sciences, Mega Traits, new enterprise fashions, and firms to motion, leading to a steady circulate of progress alternatives to drive future success. Contact us: Begin the dialogue.


Kristen Moore
E: [email protected]

About Quris
Quris, the world’s first Bio-AI clinical-prediction platform ensures the security and efficacy of latest medicine. Revolutionizing the drug improvement course of, the corporate is pioneering scientific trials on chips – testing hundreds of novel drug candidates on a whole lot of miniaturized “patients-on-a-chip”. Its absolutely automated, self-training AI platform precisely predicts scientific security and efficacy for novel medicine sooner and extra cheaply than ever earlier than – all whereas minimizing animal testing. Twin-headquartered in Boston and Israel and backed by strategic biotech and massive knowledge traders, Quris is led by a confirmed workforce of AI and medical analysis powerhouses who’re already making ready its lead discovery for scientific trials. For extra info, go to www.quris.ai. 


Erica Camilo
P: 1.610.639.5644
E: [email protected]

SOURCE Frost & Sullivan

Supply hyperlink